A potential anti-prostate cancer drug, glucosinolate-derived phenethyl isothiocyanate (PEITC), results in miR-17-5p-mediated suppression of PCAF and again AR-regulated transcriptional activity and cell growth of prostate cancer cells, suggesting a new mechanism by which PEITC modulates prostate cancer cell growth [121]. Here, AR is linked to prostate carcinoma.